Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGS-001 in Relapsed or Refractory Advanced Solid Tumors
NCT06014502Phase 1Recruiting
- Sponsor
- ImmunoGenesis
- Start
- Sep 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IMGS-001 in solid tumor, ovarian cancer, lymphoma and 3 more (6 arms), sponsored by ImmunoGenesis. Primary endpoints: Dose-Limiting Toxicities and Adverse Events at 21 days and Recommended Phase 2 Dose at 12 months. Started Sep 2023; status: recruiting.
02
Drugs
IMGS-001
03
Conditions
solid tumorovarian cancerlymphomanon-small cell lung cancer (NSCLC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06014502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014502.